Home
MYmAb Biologics is one of the top global tissue microarray company based in Malaysia. Through platforms like ArrayZeal™ and GlykoGuard™, the company aims to close global research gaps and accelerate cancer discovery for underrepresented populations.
Southeast Asia, home to nearly 700 million people, remains significantly underrepresented in global cancer research and tissue microarray studies. Despite the region’s rapid rise in cancer incidence—reporting 1.15 million new cases and 716,000 deaths in 2022—most cancer diagnostics and drug discovery pipelines still rely heavily on Western cohorts. The result: critical data gaps, limited access to targeted therapies, and a lack of inclusion in clinical research that truly reflects the region’s genetic and biological diversity.
MYmAb Biologics was founded to change that narrative. Established by Dr. Jia Xin Chua, a cancer immunologist with over a decade of research experience in the UK, the company’s mission is to make precision oncology and antibody development more accessible, representative, and impactful across Asia. Her journey home to Malaysia was driven not just by science, but by purpose—after witnessing firsthand her sibling’s struggle with cancer and the lack of advanced local treatment options.
“I came home with one goal: to make science work for Southeast Asia,” said Dr. Chua.
At the heart of MYmAb Biologics are two proprietary innovations: ArrayZeal™ and GlykoGuard™, which together position the company as one of the leading tissue microarray (TMA) companies in Asia and an emerging global player in cancer antibody discovery.
ArrayZeal™ – The Southeast Asian Tissue Microarray Platform
ArrayZeal™ is MYmAb’s flagship tissue microarray (TMA) platform, designed to revolutionize cancer research through inclusivity and precision. Each TMA block contains up to 150 well-characterized tumor specimens from Southeast Asian patients, enabling researchers and pharmaceutical companies worldwide to analyze population-specific cancer patterns efficiently.
This approach allows for:
- More representative oncology research, bridging East-West data gaps.
- Faster, more cost-effective biomarker discovery using high-quality TMA slides.
- Improved translational relevance for drug development and diagnostic validation.
By curating TMAs built on ethically sourced, well-annotated samples, MYmAb Biologics stands as a trusted tissue microarray supplier and partner for global cancer research institutions seeking to expand their datasets beyond Western populations.
GlykoGuard™ – Advancing Monoclonal Antibody Discovery
Complementing ArrayZeal™, GlykoGuard™ is MYmAb’s antibody development platform targeting cancer-associated glycans—unique sugar signatures that often appear in aggressive or treatment-resistant tumors. By focusing on these glycan markers, MYmAb is pioneering novel monoclonal antibodies (mAbs) with potential applications in both diagnostics and therapeutics.
This innovation not only strengthens MYmAb’s position as a biologics research company but also underscores its commitment to developing affordable, precision-driven solutions for cancer care in emerging markets.
Building Global-Standard Research Infrastructure in Malaysia
With strong backing from Malaysian Bioeconomy Development Corporation and Malaysian Industrial Development Finance (MIDF), MYmAb Biologics is scaling its R&D infrastructure to meet growing global demand for reliable TMA products and collaborative oncology research.
The company is actively partnering with biotech firms, CROs, and universities worldwide—proving that world-class cancer research tools can be developed in Southeast Asia.
“We’re building something world-class, right here at home,” said Dr. Chua.
By combining scientific excellence with regional insight, MYmAb Biologics is establishing itself as a top tissue microarray provider—empowering researchers, clinicians, and pharmaceutical innovators to make breakthroughs that are truly inclusive and globally relevant.
Because where you live shouldn’t determine whether you live.
“This post is written by Pillars Media, a digital marketing company in Malaysia, specializing in result-driven Google Ads, SEO, and web design services.”
